Latest: FDA Approves New Biosimilar for Oncology Treatment
Pharmaceutical

Lilly receives UK approval for pirtobrutinib in relapsed blood cancers

by PharmaTimes
0 Comments
0 Mins
MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma
Tags:
PharmaTimes
Author

PharmaTimes

Previous Post
CQC to invite GP views on updated assessment process
Next Post
FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago